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ABSTRACT A large family of isoquinoline sulfonamide
compounds inhibits protein kinases by competing with aden-
osine triphosphates (ATP), yet interferes little with the activ-
ity of other ATP-using enzymes such as ATPases and adenyl-
ate cyclases. One such compound, N-(2-aminoethyl)-5-
chloroisoquinoline-8-sulfonamide (CKI7), is selective for
casein kinase-1 isolated from a variety of sources. Here we
report the crystal structure of the catalytic domain of Schizo-
saccharomyces pombe casein kinase-l complexed with CKI7,
refined to a crystallographic R-factor of 17.8% at 2.5 A
resolution. The structure provides new insights into the
mechanism of the ATP-competing inhibition and the origin of
their selectivity toward different protein kinases. Selectivity
for protein kinases versus other enzymes is achieved by
hydrophobic contacts and the hydrogen bond with isoquino-
line ring. We propose that the hydrogen bond involving the
ring nitrogen-2 atom of the isoquinoline must be preserved,
but that the ring can flip depending on the chemical substitu-
ents at ring positions 5 and 8. Selectivity for individual
members of the protein kinase family is achieved primarily by
interactions with these substituents.
Casein kinase-1 (CK1) is an ubiquitous eukaryotic protein
kinase that phosphorylates acidic substrate recognition se-
quences (1, 2). Functionally, CK1 is known to phosphorylate
a number of proteins in vitro including SV40 T-antigen (3) and
tumor suppressor p53 (4). CK1 is also known to participate in
the DNA repair pathways in lower eukaryotes (5). Structurally,
CK1 folds, like other protein kinases, into two lobes: a small
N-terminal lobe that contains predominantly (3-sheets and a
large, mostly a-helical, C-terminal lobe (6). The two lobes are
connected by a single loop formed by a conserved decapeptide
segment (amino acids 86-95) in the CK1 family. Adenosine
triphosphate (ATP) binds in the cleft formed between the two
lobes.
By including chemical substituents at two positions of the
isoquinoline ring (positions 5 and 8; Table 1), inhibitors
selective for different protein kinases have been obtained (11,
12). Thus, individual isoquinoline sulfonamides have emerged
as important pharmacological tools for dissecting signal trans-
duction pathways. N-(2-aminoethyl)-5-chloroisoquinoline-8-
sulfonamide (CKI7), which has a chlorine at ring position 5 and
an ethylamine sulfonamide at ring position 8 (ref. 7; Table 1),
inhibits mammalian and Schizosaccharomycespombe CK1 with
a Ki of 8.5 ,LM (7) and 39 ,uM (10), respectively. We now report
on the crystal structure of a binary complex between CKI7 and
yeast catalytic domain of CK1.
MATERIALS AND METHODS
Crystallization and Data Collection. The recombinant 298-
residue catalytic core of Ckil, one of four CK1 isoforms in
fission yeast (10), was expressed and purified as described (13).
CKI7 was obtained from Seikagaku America (Rockville, MD).
The CK1-CKI7 complex was formed by mixing the protein (10
mg/ml in 10mM Mops, pH 7.0/50mM NaCl/0.1 mM EGTA/
0.1% 2-mercaptoethanol/1 mM DTT) and CKI7 (2mM in 2%
dimethyl sulfoxide; diluted from a 100-mM solution in di-
methyl sulfoxide) at room temperature. The complex was
crystallized by the hanging drop method at 16°C against a well
solution of 2% methanol, 1.4-1.7 M ammonium sulfate, and
2.5-25 mM sodium acetate at pH 4.6. Hexagonal crystals (a =
b = 98 A, c = 219 A) of considerable size (>0.5 mm) appeared
in all conditions, but they only diffracted to 3.5-A resolution.
Smaller (-0.1 mm) trigonal crystals (space group P3221, a =
b = 79.10 A, c = 120.04 A) also appeared in drops with 2.5-5
mM sodium acetate. These smaller trigonal crystals diffracted
x-rays to higher than 2.5 A resolution at beam line X12-C of
the National Synchrotron Light Source (Brookhaven National
Laboratory). Diffraction data from a single crystal were
collected at room temperature with an MAR image plate
detector, and processed using the HKL software package (ref.
14; Table 2).
Structure Determination and Refinement. The structure of
the inhibitory complex was determined by difference Fourier
synthesis using the CK1 coordinates from the CK1-MgATP
structure (6). The atomic coordinates of CK1 were refined
against the diffraction data using X-PLOR (15). Initially, a
120-cycle positional refinement followed by simulated anneal-
ing from a temperature of 3000 K to 300 K brought the
crystallographic R-factor from 34% to 25% using data in the
resolution range of 8.0-2.5 A. At this stage, the difference map
(F.-Fc, ac) clearly showed the CKI7 electron density. Subse-
quent refinement used all measured data from 31.0 to 2.5 A.
Ten rounds of positional and individual temperature refine-
ments of the protein model were carried out without CKI7.
Each round of refinement was followed by manual refitting and
placement of well-ordered solvent molecules using the graph-
ics program 0 (16), and then, bulk solvent correction using
X-PLOR. The solvent scattering density and isotropic temper-
ature factor for the solvent component were determined by
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Table 1. Chemical structure of CKI7 and different substitutions at positions 5 and 8
al 7 6
H2N-CH2-CH2-NH-Sl / \
O 9 10
N 42 3
Ki, IM*
Inhibitor Ring position 5 Ring position 8 CK1t cAPKt
CKI7 Cl -SO2NH(CH2)2NH2 8.5 550
CKI6 H -SO2NH(CH2)2NH2 50 >1000
H9 -SO2NH(CH2)2NH2 H 110 3.6
H89 -SO2NH(CH2)2NHCH2CH=CH- - V-Br H 38 0.05
*This table is a summary of refs. 7-9.
tMammalian CK1 from bovine testis. The K; of CKI7 for fission yeast CK1 is 39 AM (10).tMammalian cAPK from bovine heart.
minimizing the crystallographical R-factor using diffraction 188 unique conformations within 10 kcal/mol of the global
data in the lowest resolution range of 31.0-6.0 A (1loo minimum, among which 56 conformations were within 1.0
reflections). An additional 10 rounds of refinements were kcal/mol. These 56 structures were examined using graphics
performed with the CKI7 model included. The initial CKI7 program 0(16) for best fit with cyclic AMP-dependent protein
molecule was generated using modelling program MACRO- kinase (cAPK) structure by visual inspection. The H9 molecule
MODEL (17), and manually fit into the density. The final shown here represents the best fit from these 56 candidates.
CK1-CKI7 atomic model included 157 ordered water mole-
cules and 2 sulfate ions. RESULTS AND DISCUSSION
Molecular Modelling. The N-(2-aminoethyl)-5-isoquino-
linesulfonamide (H9) molecule was modelled using molecular CK1-CKI7 Overall Structure. In the CK1-CKI7 structure,
modelling program MACROMODEL version 4.5 (17). A Monte the overall folding of CK1 and the spatial positions of its
Carlo conformational search was first performed with 5000 ordered sidechains closely resemble those found in the CK1-
internally generated trial structures. Conjugate gradient en- MgATP complex described in ref. 6. The root-mean-square
ergy minimization in the absence of solvent was carried out deviation is 0.39 A when the Ca atoms of the two structures
during the course of the conformational search, using the are least-squares aligned. In this superposition, CKI7 is found
MM2 force field of MACROMODEL. A total of 449 conforma- to occupy the same cleft that binds ATP. The isoquinoline ring
tions were found with an energy within 10 kcal/mol from the replaces the adenine ring, whereas the ethylamine sulfonamide
global minimum. These conformers were subjected to further chain of CKI7 points away from the triphosphate moiety of
energy minimization in the presence of water and resulted in ATP (Fig. 1A). Thus, it is structurally confirmed that CKI7,
Table 2. Crystallographic data and refinement
Total measured Unique
Resolution range, A Crystals reflections reflections I/a Rmerge,* %
00 - 2.3 1 94,790 18,581 -0 6.9
16,391 .2 6.2
Resolution shell, A Completeness, % (I/ao 2) R-factort, %
31.0-4.99 92.3 20.9
4.99-3.97 94.9 13.7
3.97-3.47 94.2 14.5
3.47-3.15 92.4 16.7
3.15-2.92 88.9 18.4
2.92-2.75 86.6 21.4
2.75-2.61 80.2 22.0
2.61-2.50 69.0 23.6
31.0-2.50 87.4 17.8
Root-mean-square deviation from ideality
Nonhydrogen atoms Bond lengths, A Bond angles, 0
CK1 2386 0.012 1.63
CKI7 18
Water 157
Sulfate 10
*Rmerge = 100 X I II- <I> /E<I>, where I is the measured intensity of each reflection and <I> is the intensity averaged from multiple
observations of symmetry related reflections.
tR-factor = 100 X I Fo-FC /E IFo I, where Fo and Fc are the observed and calculated structure factor amplitudes, respectively.
Biochemistry: Xu et al.
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and presumably the entire family of isoquinoline sulfonamide
inhibitors, bind their respective protein kinases stoichiomet-
rically by competing with ATP for its binding cleft (8).
Despite these similarities, two major differences in CK1
conformation are apparent in the CK1-CKI7 and CK1-
MgATP complexes. First, the sidechain of Asp'54 of loop L-89
(Fig. 1D), which hydrogen bonds with Asn'36 in the CK1-
MgATP structure, adopts a different conformation forming a
salt bridge with Lys41. In the CK1-MgATP structure, Lys4'
interacts with a and 3 phosphates of ATP and Asn'36 coor-
dinates with Mg2+. Lys4I and Asp'54 are two of the five
invariant amino acids found in protein kinases and Asn136 is
conserved in all serine/threonine kinases (19, 20). Second, the
tip of the glycine-rich l31-turn-132 motif (Ser22-Phe-Gly24; loop
L-12), which interacts with the triphosphate moiety of ATP in
the CK1-MgATP structure, is tilted toward the cleft in the
CK1-CKI7 structure.
Nucleotide-Binding Cleft: P1, P2, and P3 Sites. The nucle-
otide-binding cleft can be described as consisting of three
structurally distinctive sites designated P1, P2, and P3 (Fig.
1B). The hydrophobic P1 site hosts both the adenine ring of
ATP and the isoquinoline ring of CKI7, whereas the solvent-
accessible P2 site, comprised by many of the charged invariant
amino acids found in all protein kinases, binds the triphosphate
moiety of ATP. A third area, P3, where the ethylamine
sulfonamide chain of CKI7 binds, is also solvent accessible and
consists of sequences that vary greatly among protein kinases.
Hydrogen Bonding at P1 Site. Closer inspection reveals that
the N2 atom of the isoquinoline ring, the only nitrogen on the
isoquinoline ring, lies in a position that is occupied by the Ni
atom of the adenine ring of ATP in the CK1-ATP complex.
Both of these nitrogen atoms form hydrogen bonds with the
backbone amide of Leu88 in their respective complexes (Fig. 2
A and B), suggesting that this interaction makes an important
contribution to the binding affinity of CKI7. Crystallographic
studies of several eukaryotic protein kinases have shown
commonality in the interaction between the Ni ofATP and the
mainchain nitrogen atoms, e.g., the mainchain nitrogens of
Val123 in the cAPK (21; see Fig. 1D), Leu83 in cyclin-dependent
kinase 2 (22), Met"'16 of the MAP kinase ERK2 (23), and
Met'106 of glycogen phosphorylase kinase (24), suggesting that
this hydrogen bond between protein kinases and ATP (and
potentially isoquinoline sulfonamides) is probably conserved
in most protein kinases. Indeed, Hidaka et al. (25) noted that
naphthalene sulfonamides were not selective protein kinase
inhibitors until the ring from the all-carbon naphthalene was
changed to the nitrogen-containing isoquinoline. Moreover,
comparison of the interactions among cyclin-dependent kinase
2 with ATP and cyclin-dependent kinase 2 with two adenine
derivative inhibitors reveals only one conserved hydrogen
bond involving the NH of Leu83 (26).
CKI7 may derive additional binding energy from its exocy-
clic chlorine at isoquinoline ring position 5, which is within
hydrogen bonding distance of the hydroxyl group of Tyr59. This
tyrosine is located in the inner surface of the nucleotide
binding cleft, comprises part of the P1 site, and is conserved
in all CK1 isoforms identified to date (10).
Interactions at the P3 Site. The ethylamine sulfonamide
chain of CKI7 makes unique contacts with a number of
sidechains and water molecules in the P3 region (Figs. 1C and
2B). Part of this site is formed by the conserved decapeptide
segment (Asp86-Leu-Leu-Gly-Pro-Ser-Leu-Glu-Asp-Leu95;
loop L-5B and part of helix aB) that connects the two lobes of
CK1. The nitrogen N, (NH3+) of the ethylamine sulfonamide
chain, which is positively charged at physiological pH, interacts
with the 02 of Asp94 as well as with Ser9' and Asp94 through
two water molecules. A third water molecule bridges Ng of
CKI7 and the mainchain oxygen of Leu88. Although Leu88,
Ser9l, and Asp94 are conserved in all known CK1 isoforms (10),
the amino acid sequence diversity of the corresponding P3 sites
among different protein kinases (19, 20) indicates that this site
can be used to impart selectivity to potential inhibitors.
Isoquinoline Ring-Flipping Model. The availability of lim-
ited structure-activity relationship data for the isoquinoline
sulfonamides suggests which of the interactions described
above contribute to binding affinity and selectivity. In partic-
ular, comparison of CKI7 to N-(2-aminoethyl)-8-isoquinoline-
sulfonamide (CKI6), which lacks the chlorine at position 5, and
to H9, which contains the same substituents but at opposite
positions on the isoquinoline ring, is instructive (Table 1).
First, replacement of chlorine with hydrogen at isoquinoline
ring position 5 (as in CKI6) results in an inhibitor that is 5-fold
less potent than CKI7 against mammalian CK1. This suggests
that the interaction between chlorine at position 5 and the
hydroxyl group of Tyr59 makes a significant contribution to
CKI7 binding affinity. It must be noted, however, that CKI6 is
less potent than CKI7 toward protein kinases that are unre-
lated to CK1 (11), and that do not contain a Tyr at the
equivalent position. Thus, part of the difference in potency
between CKI6 and CKI7 may result from other considerations,
such as differences in their energies of desolvation (27, 28).
Second, switching the positions of the ethylamine sulfon-
amide chain to ring position 5 and the hydrogen to ring position
8 results in an inhibitor (H9, Table 1) that is only 2-fold less
potent than CKI6 against mammalian CK1. This is surprising,
as the structure of CK1-CKI7 predicts that the ethylamine
sulfonamide in H9 should collide with the inner surface of the
P1 site if the isoquinoline ring is oriented the same way as in
CKI7. However, if the isoquinoline ring of H9 flips over, so
that the sidechain attached to ring position 5 faces outside as
in the CK1-CKI7 structure, substituents at position 5 can be
tolerated. Assuming that the ring N2 atom maintains its
interaction with the mainchain nitrogen of Leu88 (Fig. 2C),
such flipping could still maintain some of the interactions at
the P3 site between the ethylamine sulfonamide chain and the
protein, resulting in only a modest (2-fold) loss of potency.
Although this model suggests how isoquinoline sulfonamide
selectivity among protein kinases is achieved, it is still unclear
why differences in potency are observed within the CK1 family.
For example, CKI7 inhibits fission yeast Ckil with 4-fold
FIG. 1 (on opposite page). Structure of CK1-CKI7 complex. (A) Close up of the nucleotide binding cleft of CK1 showing the superimposition
of the CKI7 and ATP (yellow). The GRASP (18) representation was computed at neutral pH and displayed at the level of the solvent-accessible
surface. Charge distribution was color-coded with blue for positive, red for negative, and white for neutral. The CKI7 is represented by a stick model
with white for carbon, dark blue for nitrogen, red for oxygen, green for sulfur, and magenta for chlorine. (B) Schematic illustration of the P1, P2,
and P3 binding sites. The isoquinoline ring occupies the same position as the adenine ring of ATP (P1), whereas the ethylamine sulfonamide at
ring position 8 (P3) extends in a different direction from the triphosphate (P2). The green cross in the lower right corner is a sulfate-binding site,
where it may bind the phosphate moiety of phosphoprotein substrates (6). (C) Stereoview of a difference electron density map (F0-Fc, ac) contoured
at 4a above the mean. The CKI7 and three water molecules (Wl, W2, and W3) were omitted in the structure factor calculation. Besides the charge
and polar interactions, the isoquinoline ring of CKI7 is also surrounded by a number of hydrophobic amino acids: three leucines, three isoleucines,
one valine, and one alanine. These van der Waals contacts (not shown) are the same as those observed for the adenine of ATP in CK1-MgATP
complex (6). One CKI7 intramolecular hydrogen bond occurs between the nitrogen N, and the oxygen O,Xi of the sulfonate group (see Fig. 2B).
(D) Structure-based amino acid sequence alignment of yeast Cki16-298 and mouse cAPK37-350. Identities are shown with vertical bars, whereas
similarities are indicated by colons. Roman numerals mark the beginning of each of the 11 protein kinase subdomains (19). Secondary structure
elements are only shown for Cki16-298. Residues highlighted in Cki16-298 are either invariant (white against black) or similar (shaded) in all known
isoforms of CK1. Residues highlighted in cAPK are those identified as being conserved in most protein kinases.
Biochemistry: Xu et al.
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weaker potency than it inhibits mammalian CK1 (7, 10). It
should be noted, however, that this lower potency for CKI7 is
mirrored by a lower Km for ATP (10), and so may result from
differences in the conformation of the nucleotide-binding cleft
that affects affinity but not selectivity. These in turn could arise
from differences in primary structure (the catalytic domain of
fission yeast and mammalian CK1 are approximately 55%
identical in sequence), or from the influence of sequences
outside the catalytic domain.
Modelling of H9 with cAPK. This ring-flipping model and
the conservation of the hydrogen bond by the ring N2 atom
also provide a possible structural explanation for the selectivity
of H9 for cAPK relative to CK1 (ref. 7; see Table 1). In the
cAPK structure, the region C terminal to the protein kinase
catalytic domain, folds back toward the N-terminal lobe (21).
One segment of this C-terminal region (Phe327-Asp328-Asp329-
Tyr330; see Fig. 1D) forms part of the P3 site in cAPK, which
may directly influence the inhibitor binding. To test the
feasibility of this model, the interaction of H9 with cAPK was
examined by molecular modelling methods (Fig. 3). When the
N2 atom of an energy-minimized model of H9 is aligned to
FIG. 2. Schematic representation showing the specific interactions
observed between (A) CKi and ATP (ref. 6; pdb code lcsn) and (B)
CK1 and CKI7. For clarity, hydrophobic and van der Waals contacts
are not shown. (C) Proposed CK1-H9 interactions. The ring N2 atom
of H9 occupies the same position where N2 of CKI7 and Nl of ATP
are anchored and makes the same hydrogen bond with the mainchain
amide of Leu88. This will cause a displacement of the H9 molecule
from the corresponding CKI7 position and alter the interactions
between the NH3+ group of the ethylamine sulfonamide and the
sidechains of Asp94 and Ser91.
hydrogen bond with the mainchain amide of Val123 in the P1
site ofcAPK the ethylamine sulfonamide chain ofH9 molecule
can be docked surprisingly well in the P3 site. In this model, the
phenyl ring of Phe327 interacts with the isoquinoline ring via
the van der Waals contacts, whereas the hydroxyl group of
Tyr330, the sidechain of Glu127 and the mainchain oxygen of
Leu49 directly interact with the NE (NH3+) of the ethylamine
sulfonamide (Fig. 3).
The existence of other isoquinoline sulfonamides with very
high affinity for cAPK, such as N-[2-(p-bromocinnamylamino)-
ethyl]-5-isoquinolinesulfonamide (H89), which binds cAPK with
a Ki of approximately 48 nM (ref. 9; see Table 1), suggest that
additional interactions exist that increase ligand affinity and
selectivity beyond those described above for H9. The long and
bulky chain at ring position 5 ofH89 could interact via a unique
hydrogen bond between its bromine atom and the sidechain
of Asp328, and by van der Waals contacts mediated by the
aromatic ring of the benzene moiety.
Summary. The structure of the CK1-CKI7 complex pro-
vides a starting point for understanding the structural basis of
the selectivity of the entire isoquinoline sulfonamide family of
6312 Biochemistry: Xu et al.
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FIG. 3. Docking model for H9 binding in cAPK (ref. 21; pdb code 4cpk). The ring N2 atom makes a hydrogen bond with the mainchain nitrogen
of Val123; the terminal NH3+ group of the ethylamine sulfonamide interacts with the sidechain of Glu127 (the homologous of Ser9l in CK1) and
Tyr330, and the mainchain of Leu49.
inhibitors, and will facilitate the rational design of more
effective protein kinase inhibitors. We have identified two
sites, P1 and P3, as key to the selectivity of the isoquinoline
sulfonamide class of ATP-competitive protein kinase inhibi-
tors. Selectivity for protein kinases versus other enzymes is
achieved by interactions in the P1 site, powered mostly by
hydrophobic contacts and the hydrogen-bond forming nitro-
gen on isoquinoline ring. We propose that the hydrogen bond
involving the ring N2 atom of the isoquinoline ring must be
preserved in the P1 site, but that the ring can flip depending
on the chemical substituents at positions 5 and 8. Selectivity for
individual members of the protein kinase family is achieved
primarily by interactions between these substituents and the P3
site, but also by specific interactions within the Pl site.
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